Subacute Intravenous Toxicity Study of Recombinant Human Erythropoietin(rHu-EPO) in Rats

랫드에서 인체 재조합 적혈구 조혈인자, rHu-EPO의 아급성정맥독성시험

  • 김형식 (성균관대학교 약학대학 독성학교실) ;
  • 곽승준 (성균관대학교 약학대학 독성학교실) ;
  • 천선아 (성균관대학교 약학대학 독성학교실) ;
  • 임소영 (성균관대학교 약학대학 독성학교실) ;
  • 박현선 (성균관대학교 약학대학 독성학교실) ;
  • 홍채영 (성균관대학교 약학대학 독성학교실) ;
  • 김원배 (동아제약(주)연구소) ;
  • 김병문 (동아제약(주)연구소) ;
  • 안병옥 (동아제약(주)연구소)
  • Published : 1996.12.01

Abstract

This study was conducted to investigate the subacute intravenous toxicity of rHu-EPO in Sprague-Dawley rats. rHu-EPO was daily administered to male and female rats for 30 days with different dose levels(100, 500, 2,500 unit/ kg). After the administration period of 30 days, 5 males and 5females rats per each dose group were assigned for recovery period of additional 30 days. There were no clinical signs compared with control group but slight decrease in spontaneous motor activities and locomotions were observed at high dose groups of males and females. In males, feed consumption was reduced at 500 unit/kg and body weight gain was retarded. In the administration sites of tail, focal congestion was observed in a few animals treated with rHu-EPO. No deaths were occurred during the course of study. In hematological examination. a significant increase of hemoglobin and hematocrit was observed in the males and females rats receiving high dose of rHu-EPO. rHu-EPO administration for 30 days showed a marked decrease in glucose concentration. At the highest dose groups, there was a significant incerase in the weights of spleens in both sexes. but this was considered to be related to its pharmacological activity. These results indicate that rHu-EPO does not induce any significant toxic effect on Sprague-Dawley rats for 30 days.

Keywords

References

  1. Biochemistry v.26 Characterization of recombinant human erythropoietin production in Chinese hamster ovary cells Davis,J.M.;Arakawa,R.;Strickland,T.W.;Yphantis,D.A.
  2. Br. J. Haematol. v.45 Renal and extrarenal erythropoietin production in anaemic rats Erslev,A.J.;Caro,J.;Kansu,E.;Silver,R.
  3. JAMA v.263 The quality of life of hemodialysis recipients treated with recombinant human erythropoietin Evans,R.W.;Rader,B.;Manninen,D.L.;the Cooperative Multicenter EPO Clinical Trial Group
  4. Progress in Drug Research v.41 Recent advances in erythropoietin research Fisher,J.W.;Ernst Jucker(ed.)
  5. Korean J. Toxicol. v.10 Subacute toxicity of recombinant human erythropoietin in rats Kim,D.H.;Lim,D.M.L.;Cho,H.J.;Park,K.H.;Ha,B.J.;Kim,H.S.
  6. Arch. Toxicol. v.54 A new approach to practical toxicity testing Lorke,D.
  7. 藥理と治療 v.18 General Pharmacological studies of erythropoietin(TYB-5220) Mino,T.;Ohmura,T.;Hiraoka,Y.;Sugino,T.;Hayashi,H.
  8. Toxicity test guideline for safety evaluation of drugs for human use, No. 94-3 Korea National Institute of Safety Research
  9. 藥理と治療 v.18 no.SUP.5 Acute subcutaneous and intravenous toxicity studies in rats and monkeys with TYB-5220 Spicer,E.J.F.;Wisler,J.A.
  10. Drugs v.38 Treatment of the anemia of chronic renal falure with recombinant human erythropoietin Wineals,C.G.